Antioxidants · 15 authors, 13 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
In a prospective cohort of 240 ambulatory chronic heart failure patients followed for a mean of 5.78 years, serum FABP3 and FABP4 independently predicted all-cause and cardiovascular mortality specifically in subjects with type 2 diabetes mellitus, but not in those without T2D.
A prospective cohort study of 240 ambulatory chronic heart failure patients (median age 69 years, 47.5% with T2D) followed for a mean of 5.78 years assessed whether baseline serum FABP3 and FABP4 predicted mortality. Subjects with T2D had higher mortality rates (69.30% vs. 50.79%, p=0.004) and higher FABP3 and FABP4 concentrations. In the whole cohort, FABP3 independently predicted all-cause death, and both FABP3 and FABP4 predicted CV mortality. In the T2D subgroup, FABP3 predicted all-cause mortality (HR 1.25, 95% CI 1.09–1.44, p=0.002) and CV death (HR 1.28, 95% CI 1.09–1.50, p=0.002), while FABP4 predicted all-cause mortality (HR 2.21, 95% CI 1.12–4.36, p=0.023) and CV death (HR 4.19, 95% CI 2.21–7.95, p<0.001). FABP4 also predicted the composite endpoint in T2D subjects (HR 2.07, 95% CI 1.11–3.87, p=0.022). None of these associations were significant in non-T2D subjects. Limitations include the single-center design, relatively small sample size, and retrospective data elements precluding causal inference.
